BBI Solutions (BBI) has increased its antibodies range across a wide variety of disease areas including bone metabolism, cardiac, growth factors, thyroid, and sepsis. This range extension has been in response to growing demand in the IVD market.
The IVD industry is estimated to grow to $75.1 billion by 2020, at a CAGR of 5.8% from 2015 to 2020¹. BBI has already noticed an increased demand for antibodies and have expanded their antibodies range in response to customer enquiries.
Some of the products already proving to be popular in the new range are Vitamin D2 and D3, Procalcitonin and NT-proBNP.
The Vitamin D2 and D3 products will help with the diagnosis and monitoring of Vitamin D deficiencies. Deficiencies in Vitamin D can be a risk factor for a number of medical conditions including, osteomalacia, rickets and osteoporosis.
Procalcitonin (PCT) is a marker for early sepsis diagnosis. Levels in the blood of healthy patients are usually very low. However, levels can increase quickly within 3-6 hours of systemic infections or inflammation caused by bacterial infections. Therefore, PCT antibodies can be used in assays to monitor the progression of the disease and the effectiveness of treatment².
NT-proBNP is a biomarker used in the diagnosis of heart failure. Raised levels are associated with increased mortality in heart failure patients.
¹ In Vitro Diagnostics (IVD) Market by Product (instruments, Reagents, Software, Service) Technology (Immunoassay, Clinical Chemistry, Molecular Diagnostics, Hematology) by Application (Diabetes, Cancer, Cardiology, Autoimmune Diseases) - Forecast to 202); marketsandmarkets.com, Publishing Date: July 2015, Report Code: MD 3609.
² Procalcitonin and the Calcitonin Gene Family of Peptides in Inflammation, Infection, and Sepsis: A Journey from Calcitonin Back to its Precursors J. Becker et al., The Journal of Clinical Endocrinology & Metabolism 89(4):1512–1525.